线粒体DNA遗传变异与系统性红斑狼疮易感性、糖皮质激素疗效及预后相关
两阶段研究对605例SLE患者和604例正常对照进行线粒体全基因组测序及验证,发现4个mtDNA变异与SLE易感性相关,T16362C与糖皮质激素疗效相关,A4833G和G14569A增加复发风险,单倍群G与易感性和预后相关,并观察到mtDNA变异与环境交互作用。
要点
- A4833G、T5108C、G14569A、CA514-515-四个mtDNA变异与SLE易感性相关(所有PBH<0.05)。
- T16362C与糖皮质激素疗效相关(PBH=0.014),女性中T16362C和T16519C亦与疗效相关(PBH<0.05)。
- A4833G(PBH=0.003)和G14569A(PBH=9.744×10-4)增加SLE复发风险,单倍群G与易感性(PBH=0.001)和预后(PBH=0.013)相关。
核心结论
- 研究识别出与SLE易感性、糖皮质激素疗效及预后相关的新mtDNA遗传变异,mtDNA变异与环境因素的交互作用与SLE风险和糖皮质激素疗效相关,为未来理解SLE发生发展提供重要信息。
研究设计与样本
- 两阶段研究:第一阶段对100例患者和100例对照进行线粒体全基因组测序初步筛选与疾病和糖皮质激素疗效相关的mtDNA变异,第二阶段在独立样本中验证,共纳入605例SLE患者和604例正常对照。
- 两阶段疗效研究在512例接受糖皮质激素治疗12周的患者中进行,并探索mtDNA变异与SLE预后的关联。
主要发现
- 在合并样本中,A4833G、T5108C、G14569A、CA514-515-四个mtDNA变异与SLE易感性相关(所有PBH<0.05)。
- T16362C与糖皮质激素疗效相关(PBH=0.014),女性SLE患者中T16362C和T16519C与糖皮质激素疗效显著相关(PBH<0.05)。
- 预后研究中,A4833G(PBH=0.003)和G14569A(PBH=9.744×10-4)大幅增加SLE复发风险,携带T5108C和T16362C的女性患者更易复发(PBH<0.05)。
- 单倍型分析显示单倍群G与SLE易感性(PBH=0.001)和预后(PBH=0.013)相关,并观察到mtDNA变异与环境交互作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the associations of mitochondrial DNA (mtDNA) genetic variants with SLE susceptibility, glucocorticoid (GC) efficacy and prognosis. METHODS: Our study was done in two stages. First, we performed whole mitochondrial genome sequencing in 100 patients and 100 controls to initially screen potential mtDNA variants associated with disease and GC efficacy. Then, we validated the results in an independent set of samples. In total, 605 SLE patients and 604 normal controls were included in our two-stage study. A two-stage efficacy study was conducted in 512 patients treated with GCs for 12 weeks. We also explored the association between mtDNA variants and SLE prognosis. RESULTS: In the combined sample, four mtDNA variants (A4833G, T5108C, G14569A, CA514-515-) were associated with SLE susceptibility (all PBH < 0.05). We confirmed that T16362C was related to efficacy of GCs (PBH = 0.014). Significant associations were detected between T16362C and T16519C and the efficacy of GCs in females with SLE (PBH < 0.05). In the prognosis study, variants A4833G (PBH = 0.003) and G14569A (PBH = 9.744 × 10-4) substantially increased SLE relapse risk. Female patients harbouring variants T5108C and T16362C were more prone to relapse (PBH < 0.05). Haplotype analysis showed that haplogroup G was linked with SLE susceptibility (PBH = 0.001) and prognosis (PBH = 0.013). Moreover, mtDNA variant-environment interactions were observed. CONCLUSION: We identified novel mtDNA genetic variants that were associated with SLE susceptibility, GC efficacy, and prognosis. Interactions between mtDNA variants and environmental factors were related to SLE risk and GC efficacy. Our findings provide important information for future understanding of the occurrence and development of SLE.
引用
- Teng Y, Yan ZY, Wang LL, et al. Mitochondrial DNA genetic variants are associated with systemic lupus erythematosus susceptibility, glucocorticoids efficacy and prognosis. Rheumatology (Oxford). 2022. PMID: 34718439. doi:10.1093/rheumatology/keab806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。